These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

804 related items for PubMed ID: 21699645

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Gosselaar C, Roobol MJ, Roemeling S, van der Kwast TH, Schröder FH.
    Prostate; 2007 Feb 01; 67(2):154-61. PubMed ID: 17044079
    [Abstract] [Full Text] [Related]

  • 45. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul 01; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 46. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS.
    BJU Int; 2013 Mar 01; 111(3):396-403. PubMed ID: 22703025
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May 01; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 53. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K.
    Int J Urol; 2007 Aug 01; 14(8):713-8. PubMed ID: 17681061
    [Abstract] [Full Text] [Related]

  • 54. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb 01; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 55. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Feb 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 56. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA.
    N Engl J Med; 2004 May 27; 350(22):2239-46. PubMed ID: 15163773
    [Abstract] [Full Text] [Related]

  • 57. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK, Oh JJ, Byun SS, Hwang SI, Choo MS, Lee SE.
    BJU Int; 2012 Jul 27; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [Abstract] [Full Text] [Related]

  • 58. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, Roobol MJ.
    Eur Urol; 2012 Feb 27; 61(2):370-7. PubMed ID: 21704447
    [Abstract] [Full Text] [Related]

  • 59. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 60. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.
    Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H.
    BJU Int; 2012 Oct 01; 110(7):993-7. PubMed ID: 22394668
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.